By Tom Hals (Reuters) - A Delaware judge on Wednesday ordered Siga Technologies Inc, a supplier of an antiviral smallpox drug to the U.S. strategic stockpile, to pay PharmAthene Inc $113.1 million in damages in a licensing dispute. The Delaware Court of Chancery on Aug. 8 ruled that PharmAthene is entitled to damages from Siga for its failure to execute a license agreement related to its main antiviral smallpox drug, Tecovirimat. Wednesday's ruling determined those damages, which are to include as-yet unspecified prejudgment interest, according to court documents. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment